Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 29

PMID 33777739

Citations 26

Authors

Xiaoyang Zhang

Cheng Wei

Hao Liang

Lei Han

Affiliations

Soon will be listed here.

Abstract

Polo-like kinases (Plks) are critical regulatory molecules during the cell cycle process. This family has five members: Plk1, 2, 3, 4, and 5. Plk4 has been identified as a master regulator of centriole replication, and its aberrant expression is closely associated with cancer development. In this review, we depict the DNA, mRNA, and protein structure of Plk4, and the regulation of Plk4 at a molecular level. Then we list the downstream targets of Plk4 and the hallmarks of cancer associated with these targets. The role of Plk4 in different cancers is also summarized. Finally, we review the inhibitors that target Plk4 in the hope of discovering effective anticancer drugs. From authors' perspective, Plk4 might represent a valuable tumor biomarker and critical target for cancer diagnosis and therapy.

Citing Articles

A Comprehensive Review of Protein Biomarkers for Invasive Lung Cancer.

Mezentsev A, Durymanov M, Makarov V Curr Oncol. 2024; 31(9):4818-4854.

PMID: 39329988 PMC: 11431409. DOI: 10.3390/curroncol31090360.

Centrosomes and associated proteins in pathogenesis and treatment of breast cancer.

Athwal H, Kochiyanil A, Bhat V, Allan A, Parsyan A Front Oncol. 2024; 14:1370565.

PMID: 38606093 PMC: 11007099. DOI: 10.3389/fonc.2024.1370565.

Centrosome amplification and aneuploidy driven by the HIV-1-induced Vpr•VprBP•Plk4 complex in CD4 T cells.

Park J, Kim T, Zeng Y, Mikolaj M, Il Ahn J, Alam M Nat Commun. 2024; 15(1):2017.

PMID: 38443376 PMC: 10914751. DOI: 10.1038/s41467-024-46306-8.

PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer.

Pellizzari S, Bhat V, Athwal H, Cescon D, Allan A, Parsyan A Radiat Oncol. 2024; 19(1):24.

PMID: 38365710 PMC: 10873955. DOI: 10.1186/s13014-024-02410-z.

Tumor polo-like kinase 4 protein expression reflects lymphovascular invasion, higher Federation of Gynecology and Obstetrics stage, and shortened survival in endometrial cancer patients who undergo surgical resection.

Zhao Q, Wang M, Chen M BMC Womens Health. 2024; 24(1):101.

PMID: 38326803 PMC: 10851612. DOI: 10.1186/s12905-024-02911-9.

References

Kazazian K, Go C, Wu H, Brashavitskaya O, Xu R, Dennis J . Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton. Cancer Res. 2016; 77(2):434-447. DOI: 10.1158/0008-5472.CAN-16-2060. View

Morris E, Kawamura E, Gillespie J, Balgi A, Kannan N, Muller W . Stat3 regulates centrosome clustering in cancer cells via Stathmin/PLK1. Nat Commun. 2017; 8:15289. PMC: 5424153. DOI: 10.1038/ncomms15289. View

Koskela P, Anttila T, Bjorge T, Brunsvig A, Dillner J, Hakama M . Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer. 1999; 85(1):35-9. DOI: 10.1002/(sici)1097-0215(20000101)85:1<35::aid-ijc6>3.0.co;2-a. View

Anastasiadi Z, Lianos G, Ignatiadou E, Harissis H, Mitsis M . Breast cancer in young women: an overview. Updates Surg. 2017; 69(3):313-317. DOI: 10.1007/s13304-017-0424-1. View

Godinho S, Picone R, Burute M, Dagher R, Su Y, Leung C . Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014; 510(7503):167-71. PMC: 4061398. DOI: 10.1038/nature13277. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Kitagawa D, Vakonakis I, Olieric N, Hilbert M, Keller D, Olieric V . Structural basis of the 9-fold symmetry of centrioles. Cell. 2011; 144(3):364-75. PMC: 3089914. DOI: 10.1016/j.cell.2011.01.008. View

Kent L, Bae S, Tsai S, Tang X, Srivastava A, Koivisto C . Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest. 2017; 127(3):830-842. PMC: 5330731. DOI: 10.1172/JCI87583. View

Bao J, Yu Y, Chen J, He Y, Chen X, Ren Z . MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis. 2018; 9(10):1045. PMC: 6185973. DOI: 10.1038/s41419-018-1020-0. View

10.

Sampson P, Liu Y, Patel N, Feher M, Forrest B, Li S . The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents. J Med Chem. 2014; 58(1):130-46. DOI: 10.1021/jm5005336. View

11.

Carvalho-Santos Z, Machado P, Branco P, Tavares-Cadete F, Rodrigues-Martins A, Pereira-Leal J . Stepwise evolution of the centriole-assembly pathway. J Cell Sci. 2010; 123(Pt 9):1414-26. DOI: 10.1242/jcs.064931. View

12.

Liang Wong Y, Anzola J, Davis R, Yoon M, Motamedi A, Kroll A . Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science. 2015; 348(6239):1155-60. PMC: 4764081. DOI: 10.1126/science.aaa5111. View

13.

Simmons D, Neel B, Stevens R, Evett G, Erikson R . Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol Cell Biol. 1992; 12(9):4164-9. PMC: 360319. DOI: 10.1128/mcb.12.9.4164-4169.1992. View

14.

Chng W, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R . The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood. 2007; 111(3):1603-9. DOI: 10.1182/blood-2007-06-097774. View

15.

Liu Y, Kim J, Philip R, Sridhar V, Chandrashekhar M, Moffat J . Direct interaction between CEP85 and STIL mediates PLK4-driven directed cell migration. J Cell Sci. 2020; 133(8). PMC: 7183410. DOI: 10.1242/jcs.238352. View

16.

Wang J, Ren D, Sun Y, Xu C, Wang C, Cheng R . Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway. J Cell Mol Med. 2020; 24(7):3931-3947. PMC: 7171416. DOI: 10.1111/jcmm.14996. View

17.

Li Z, Dai K, Wang C, Song Y, Gu F, Liu F . Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy. J Cancer. 2016; 7(9):1125-32. PMC: 4911880. DOI: 10.7150/jca.14307. View

18.

Brownlee C, Klebba J, Buster D, Rogers G . The Protein Phosphatase 2A regulatory subunit Twins stabilizes Plk4 to induce centriole amplification. J Cell Biol. 2011; 195(2):231-43. PMC: 3198173. DOI: 10.1083/jcb.201107086. View

19.

Li Y, Xuan J, Song Y, Qi W, He B, Wang P . Nanoporous Glass Integrated in Volumetric Bar-Chart Chip for Point-of-Care Diagnostics of Non-Small Cell Lung Cancer. ACS Nano. 2015; 10(1):1640-7. PMC: 4934604. DOI: 10.1021/acsnano.5b07357. View

20.

Repasky G, Chenette E, Der C . Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol. 2004; 14(11):639-47. DOI: 10.1016/j.tcb.2004.09.014. View